STOCK TITAN

Pro-Dex (PDEX) issues press release on Q2 and six-month 2025 results

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Pro-Dex, Inc. furnished an update on its recent financial results by announcing that it issued a press release covering its financial performance for the second quarter and six months ended December 31, 2025. The company attached this press release as Exhibit 99.1 to the current report.

The report clarifies that the press release and related information are being furnished rather than filed for liability purposes under securities laws. The filing also includes an exhibit for the cover page interactive data file and is signed on behalf of the company by its Chief Financial Officer, Alisha K. Charlton.

Positive

  • None.

Negative

  • None.
false 0000788920 0000788920 2026-01-29 2026-01-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): January 29, 2026

 

PRO-DEX, INC.

(Exact name of registrant as specified in charter)

 

Colorado 0-14942 84-1261240
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification Number)

 

2361 McGaw Avenue

Irvine, California 92614

(Address of principal executive offices, zip code)

 

(949) 769-3200

(Registrant’s telephone number including area code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Exchange Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, no par value PDEX NASDAQ Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company    

 

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

 

 
 

 

 

 

 
 

 

Item 2.02.Results of Operations and Financial Condition.

The information in this Item 2.02 of this Form 8-K, as well as Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

On January 29, 2026, Pro-Dex, Inc. (the “Company”) is issuing a press release announcing its financial performance for the second quarter and six months ended December 31, 2025. A copy of the press release is attached to this Form 8-K as Exhibit 99.1, which is incorporated herein by this reference.

    

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit Number Description
99.1

Press Release dated January 29, 2026

104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)

 

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: January 29, 2026 Pro-Dex, Inc.
   
     
  By: /s/ Alisha K. Charlton
    Alisha K. Charlton
    Chief Financial Officer

 

 

 

 

FAQ

What did Pro-Dex (PDEX) disclose in this 8-K filing?

Pro-Dex disclosed that it issued a press release announcing its financial performance for the second quarter and six months ended December 31, 2025. The press release is attached as Exhibit 99.1 and incorporated by reference in the report.

Which financial period does Pro-Dex’s latest press release cover?

The press release covers Pro-Dex’s financial performance for the second quarter and the six-month period ended December 31, 2025. Specific revenue or earnings figures are contained in Exhibit 99.1, which accompanies the current report.

How is the Pro-Dex (PDEX) press release treated under securities laws?

The information in Item 2.02 and Exhibit 99.1 is expressly stated as being furnished, not filed, for purposes of Section 18 of the Exchange Act. It is not incorporated into other filings unless specifically referenced by the company.

What exhibits are included with Pro-Dex’s January 2026 8-K?

The filing includes Exhibit 99.1, a press release dated January 29, 2026, discussing financial performance, and Exhibit 104, a cover page interactive data file containing the embedded inline XBRL tags for the report’s cover page information.

Who signed the Pro-Dex (PDEX) 8-K current report?

The current report was signed on behalf of Pro-Dex, Inc. by Alisha K. Charlton, the company’s Chief Financial Officer. Her signature indicates that she is the duly authorized officer executing the filing for the registrant.

On which exchange is Pro-Dex common stock listed and under what symbol?

Pro-Dex’s common stock, with no par value, is listed on the NASDAQ Capital Market. The trading symbol for the company’s common stock is PDEX, as identified in the securities registration section of the report.
Pro-Dex Inc Colo

NASDAQ:PDEX

PDEX Rankings

PDEX Latest News

PDEX Latest SEC Filings

PDEX Stock Data

123.27M
2.09M
35.94%
32.91%
7.98%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States
IRVINE